@davidasinclair The damage isn’t CRISPR-specific—it’s any DSB.
Obesity drives 10,000–100,000 ROS-induced DSBs/cell/day in fat & liver (γH2AX data). A single CRISPR edit? ~1–10 DSBs once.
That’s 10⁴–10⁵× more daily epigenetic chaos from cheeseburgers than Cas9. Perspective matters.
@zhaoweiasu Do you think it’s fair to say toxicity is not inevitable—it’s detectable and manageable. With sentinel monitoring + preemptive pharmacology.
@boringmarketer Mind blown regarding the speed to value with very little budget. I think this illustrates the future's most valuable marketers are those with a broad skill set that understand how the various marketing disciplines fit together for a truly integrated approach.
@Biotech2k1@ksttslns Did something change your mind about RNAi? Or more a matter of diversification across different technologies/clinical applications?
@Biotech2k1 I love the $dna platform approach. Are you familiar with $sybx or other high spec stocks using their platform? Any interesting use cases that have your interest?
@chiefmartec Ignorance & change mgmt IMO. Martech is good when integrated properly with processes (hard to do). And once it’s done, something changes. People’s roles in the business change. Requirements change. This is a loaded subject. No single source of blame. Shared effort & challenge.